New second-in-command for Dutch medicines agency
This article was originally published in SRA
The Dutch Medicines Evaluation Board has appointed Stan van Belkum as its new deputy director in place of Rob de Haan, who has moved to a new role at the Health Care Inspectorate1.
You may also be interested in...
Swissmedic will scale back its review procedure for certain anti-infectives if the indications for which approval is being sought are identical to those approved in the EU or the US.
Based on the operational experience gained using the new international standard for reporting suspected adverse reactions in EudraVigilance, the EU has decided to set a date for its mandatory use.
The UK’s Health Research Authority has agreed in principle to implement a new policy that aims to drive a lasting change in clinical trial transparency. Not everyone is convinced.